SGI
KRYS icon

Summit Global Investments’s Krystal Biotech KRYS Stock Holding History

Summit Global Investments’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$805K Buy
+2,167
New +$647K 0.04% 249
2025
Q3 		– Sell
-4,547
Closed -$625K – 518
2025
Q2 		$625K Sell
4,547
-164
-3% -$24.1K 0.04% 269
2025
Q1 		$849K Buy
4,711
+1,258
+36% +$212K 0.06% 193
2024
Q4 		$541K Buy
+3,453
New +$613K 0.03% 348

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Summit Global Investments's KRYS Position: Q2 2026 in Review

Summit Global Investments opened a new position in Krystal Biotech (KRYS) in Q2 2026: 2,167 shares worth $805K. The stake represents 0.04% of the portfolio and ranks #249 among its holdings. This is a return to the name: Summit Global Investments previously reported a position in KRYS as recently as Q2 2025.

Summit Global Investments first reported a position in KRYS in Q4 2024 and has held it in 4 quarters since. The position peaked at $849K in Q1 2025. 423 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

  • Summit Global Investments held 2,167 shares of Krystal Biotech worth $805K as of Q2 2026.
  • Krystal Biotech was a new Summit Global Investments position in Q2 2026.
  • Krystal Biotech made up 0.04% of Summit Global Investments's portfolio in Q2 2026, its #249 holding.
  • Summit Global Investments first reported a position in Krystal Biotech in Q4 2024 and has held it in 4 quarters since.
  • Summit Global Investments's Krystal Biotech position peaked at $849K in Q1 2025.
  • 423 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on Summit Global Investments's 13F filing for Q2 2026, filed 3 Aug 2026.